View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 29, 2018

Daiichi Sankyo and partners to research on new cancer therapy

Daiichi Sankyo, along with Nagoya City University, Chubu University, and Mitsubishi UFJ Capital, is set to begin research on the development of a new cancer hyperthermia therapy.

Daiichi Sankyo, along with Nagoya City University, Chubu University, and Mitsubishi UFJ Capital, is set to begin research on the development of a new cancer hyperthermia therapy.

Cancer hyperthermia therapy selectively kill cancer cells through heating and can be combined with radiotherapy, chemotherapy and cancer immunotherapy.

The proposed cancer hyperthermia therapy seeks to achieve high safety and efficacy by specifically heating cancer cells at a constant temperature.

The newly agreed three-year partnership will be based on the results of the Take a New Challenge for Drug discovery programme, a research initiative operated by Daiichi Sankyo.

The aim of the initiative is to identify and optimise magnetic nanoparticles with a high capacity for delivery into tumours and study their practical application as a new hyperthermia therapy for cancer.

“The proposed cancer hyperthermia therapy seeks to achieve high safety and efficacy by specifically heating cancer cells at a constant temperature.”

A new company named OiDE RYO-UN (RYO-UN) has been established to conduct the research.

Based in Chuo-ku, Tokyo, Japan, RYO-UN will receive funding from Mitsubishi UFJ Capital’s Open innovation for the Development of Emerging technologies fund. This is the third investment made by the fund.

Dependent on the success of the pre-agreed goals of the research, Daiichi Sankyo will buy all the stocks of RYO-UN to continue to develop the project itself.

After launching the product, Daiichi Sankyo is expected to pay considerations to Nagoya City University and Chubu University in the form of royalties.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU